EDITORIAL STANDARDS

Make the uncertainty visible.

A useful answer explains what the research found, who it applies to, and what it cannot establish.

THE RESEARCH TEAM

Primary investigators

Launch review · 3 October 2026

This is an AI-assisted, selected-source research library. It has not undergone independent clinical peer review and is not a systematic review.

What our evidence grades mean

Grades apply to a defined question: peptide × outcome × population × formulation or route. Assessed outcomes retain their recorded High, Moderate, Low, or Very low label. No direct human evidence and Not appraised are separate states. They describe the strength of the selected evidence, not effect size, legal status, product quality, or whether someone should use a substance. These are simplified editorial assessments, not formal GRADE ratings.

High

A directly relevant, well-designed human trial provides a comparatively strong basis for the specific finding described. Important limits still apply; this does not imply a comprehensive review or a recommendation to use the peptide.

Moderate

Direct human evidence is useful, but study design, follow-up selection, or other limitations reduce certainty.

Very low

The recorded assessment has very serious limitations. This is distinct from Low and remains a source-specific editorial judgment, not a formal GRADE rating.

No direct human evidence

The selected sources do not directly establish the stated outcome in humans. This is an evidence gap, not a Low rating of demonstrated human benefit.

Not appraised

An outcome assessment has not been completed or its label is unrecognized. Missing assessment is not a certainty rating.

Low

The evidence is limited, sparse, or indirect for the stated outcome. This includes small or uncontrolled human studies, animal or laboratory findings, product-testing observations, and findings about a different outcome or formulation. These limitations substantially reduce confidence in broader conclusions.

For example, a study showing higher growth hormone can support a statement about that biomarker. It cannot establish better sleep, stronger muscles, or faster recovery unless those outcomes were measured. When the selected sources provide no direct human evidence for an outcome, that gap is shown explicitly rather than converted to Low. Study populations and specific limitations are described alongside the evidence.

How questions are selected

Public Reddit searches targeted peptide names alongside efficacy, safety, route, comparisons, and product quality. Questions were paraphrased, without retaining usernames or personal medical histories. The sample documents community interest; it does not measure prevalence or justify “most asked” rankings. Question provenance is available separately.

Citation placement

Every factual sentence in a research answer has an inline superscript citation immediately after its closing punctuation. References are numbered from [1] in order of first appearance on each page; repeated sources retain their number. Citation groups are shown in ascending order, and each number links to the matching entry in the page’s References section. Source previews identify the study or regulatory document; evidence gaps are limited to the sources reviewed. Safety findings, precautions, and established contraindications are kept distinct.

How evidence is interpreted

Each answer opens with a direct conclusion and stays within one paragraph. Primary human studies are prioritized for clinical claims. The study design, population, route, measured outcome, and major limitations are recorded alongside the answer. Regulatory documents supply regulatory or safety context; they do not establish clinical efficacy. Animal or laboratory findings are not treated as demonstrated human benefit.

Searches used peptide names, common aliases, and question-specific terms in publicly indexed PubMed, journal, and official regulatory material. This launch review did not run an exhaustive database search, register a protocol, pool effect estimates, or perform a formal risk-of-bias assessment. Abstract-only access, selective availability, missing studies, sponsor influence, and publication bias may affect these summaries.

Formulation and safety rules

Findings remain tied to the molecule, route, and product studied. We require separate assessments for different molecules, topical and injected formulations, and approved and unapproved products. We report the observation period and sample limitations when summarizing adverse events.

Updates and scope

The dates on these pages describe the most recent source check for this launch edition. This site does not currently perform automated literature surveillance. Content changes should preserve the question, source links, formulation, rationale for the grade, and check date so conclusions can be revisited when new studies appear. The library provides education, not individual treatment or administration instructions.

Independence and attribution

This site contains no peptide sales or vendor recommendations. Its reference structure was informed by Examine’s publicly documented organization of interventions, outcomes, and FAQs, while the wording, visual identity, and grading scheme here are original. Peptides Anonymous is not affiliated with or endorsed by Examine. View the structural reference.